Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy

Histopathology

Volumn 55, Issue 4, 2009, Pages 399-406

  Fareed, Khaleel R ^a   Ilyas, Mohammad ^a   Kaye, Philip V ^a   Soomro, Irshad N ^b   Lobo, Dileep N ^b   Parsons, Simon L ^b   Madhusudan, Srinivasan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Gastro oesophageal cancers; Neoadjuvant chemotherapy; Tumour regression grade

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; PLATINUM;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER INVASION; CANCER SURGERY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; HISTOPATHOLOGY; HUMAN; LOWER ESOPHAGUS SPHINCTER; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; TUMOR REGRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PLATINUM; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 70349902782     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03404.x     Document Type: Article

References (13)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998 83 2049 2053.
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991 265 1287 1289.
3. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin. Radiat. Oncol. 2007 17 2 9.
4. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr., Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann. Surg. 1993 218 583 592.
5. Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat. Rev. 2004 30 451 459.
6. Law SY, Fok M, Cheng SW, Wong J. A comparison of outcome after resection for squamous cell carcinomas and adenocarcinomas of the esophagus and cardia. Surg. Gynecol. Obstet. 1992 175 107 112.
7. Lerut T, De Leyn P, Coosemans W, Van Raemdonck D, Scheys I, LeSaffre E. Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann. Surg. 1992 216 583 590.
8. Orringer MB. Multimodality therapy for esophageal carcinoma - update. Chest 1993 103 406S 409S.
9. Lieberman MD, Shriver CD, Bleckner S, Butt M. Carcinoma of the esophagus. Prognostic significance of histologic type. J. Thorac. Cardiovasc. Surg. 1995 109 130 138.
10. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006 355 11 20.
11. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002 359 1727 1733. R
12. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994 73 2680 2686.
13. Rudiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann. Surg. 2000 232 353 361.